Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study

The Lancet Gastroenterology & Hepatology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles